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Abstract
The National Institute on Drug Abuse and Joint Institute for Biological Sciences at
the Oak Ridge National Laboratory hosted a meeting attended by a diverse group of
scientists with expertise in substance use disorders (SUDs), computational biology,
and FAIR (Findability, Accessibility, Interoperability, and Reusability) data sharing. The
meeting's objective was to discuss and evaluate better strategies to integrate genetic,
epigenetic, and 'omics data across human and model organisms to achieve deeper
mechanistic insight into SUDs. Specific topics were to (a) evaluate the current state
of substance use genetics and genomics research and fundamental gaps, (b) identify
opportunities and challenges of integration and sharing across species and data types,
(c) identify current tools and resources for integration of genetic, epigenetic, and phe-
notypic data, (d) discuss steps and impediment related to data integration, and
(e) outline future steps to support more effective collaboration—particularly between
animal model research communities and human genetics and clinical research teams.
This review summarizes key facets of this catalytic discussion with a focus on new
opportunities and gaps in resources and knowledge on SUDs.
K E YWORD S
cross-species, data integration, drug abuse, genomics, GWAS, model organisms, multi-omic,
substance use disorders, working group
1 | INTRODUCTION
On May 29–31, 2019, the National Institute on Drug Abuse (NIDA)
and the Joint Institute for Biological Sciences at the Oak Ridge
National Laboratory (ORNL) hosted the Addiction Genetics and Epige-
netics Data Jamboree meeting at Oak Ridge, Tennessee. Over 30 sci-
entists with expertise in genetics and genomics of substance use in
human and model organisms gathered to discuss linking data and
results across systems that exploit genetics, genomics, epigenetics,
and other omics by leveraging innovative statistical methods and com-
putational tools. The meeting commenced with an open discussion of
the state of substance use genetics, including the strengths and weak-
nesses of various approaches to genotype–phenotype associations in
humans and model organisms. Most notably, researchers discussed
how joint data- and theory-driven studies using integrative cross-
species and multi-omics approaches could more rapidly discover and
translate mechanisms than relying upon genome-wide association
studies (GWAS) or model organisms alone. Over the course of 2 days,
researchers participated in thematic discussions that centered on the
current state of knowledge, gaps in understanding and advantages
and challenges of: (1) Data analyses using multi-species and multi-
omic data, (2) data integration methods/procedures, and (3) multi-
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omic data generation and sharing/accessibility. Meeting participants
reconvened on the third day to summarize findings and since then
have reflected upon the field's latest findings around the meeting's
topical areas in the preparation of the current document. Each
researcher brought their unique experience, perspective, and exper-
tise to these discussions, and a consensus was not always reached for
the best path forward on every topic. Not all authors of this report
necessarily endorse all ideas presented herein.
This report aims to summarize the discussions by focusing on the
state of science, including opportunities for more effective cross-talk
and collaboration between human and model organism research com-
munities, as well as barriers to data acquisition and integration. Next,
we discuss the methods and tools used for genetic and genomic dis-
covery, their assumptions and limitations, as well as areas for improve-
ment needed to achieve rapid translation of genetic loci to identified
mechanisms and potential treatments. We review challenges of data
transportability and sharing (i.e., Findability, Accessibility, Interopera-
bility, and Reusability data practices), for which there are interper-
sonal, legal, and technological barriers of integrating diverse data
types. Finally, we describe some gaps to address in future programs
on substance use disorders (SUDs).
1.1 | Status of substance use and disorders
genetics and genomics
SUDs represent a pressing area of unmet medical, psychological, and
social needs. In 2017, alcohol and illicit substance use and disorders
resulted in 13,969 and 67,000 deaths (directly and indirectly) in the
United States, respectively,1 which was less than smoking ( 250,000
deaths), but more than liver disease (62,493 deaths)2 and diabetes
(68,558 deaths).3 Worldwide, SUDs have a relatively early onset and
contribute to approximately 21% of lost disability-adjusted life years4
(15% for smoking and second-hand smoke not counting comorbid
drug use1), emphasizing the high societal and personal cost to affected
individuals and communities. Twin- and family-based studies show
that SUDs generally have moderate to high heritability,5 with
sequence differences contributing to 50%–70% of variance in liability.
Large-scale GWASs investigating hundreds of thousands of partici-
pants have become a reliable method to localize and identify genomic
regions, genes, and common and substance-specific nucleotide differ-
ences that contribute to the heritability of the many facets of
SUDs.6-8
To date, there has been substantial progress in the characteriza-
tion of the genetic etiology of human SUDs.9-13 Data sharing, meta-
analysis, and very large sample sizes have begun to yield loci for
alcohol-,14-19 tobacco-,18,20 and cannabis-related traits.20 The past
3 years have witnessed an escalation in these discoveries for instance,
findings for alcohol use disorder (AUD) increased from one locus
(N = 14,904 cases) in 2018 to 29 independent variants in 2020
(N = 435,563, including >57,000 cases). These human GWASs have
shown that SUDs are highly polygenic. This polygenicity may be par-
tially explained by human-specific evolutionary pressures and
diagnostic heterogeneity.21 Notably, the history of SUD and psychiat-
ric GWAS has shown that more common variants with modest effect
sizes can be identified and replicated when studies are well-powered.
Yet, there are other substances of abuse for which we still lack suffi-
cient power (e.g., opioids22 and cocaine23) for unbiased identification
of the heritable components of susceptibility, severity, and relapse.
For most common diseases, the number of genome-wide significant
hits that are discovered increases sharply after a threshold sample size
that ranges from about 10,000 to 100,000.24 In the case of psychiatric
disease, it took 36,989 cases and 113,075 controls to identify 108 loci
for schizophrenia.25 A simulation study by Walters et al. suggested
that AUD and other related SUDs26 have effect size distributions simi-
lar to major depression,27 a disease that required approximately
10,000 cases to identify the first locus,28 and may require sample
sizes between 55,000 and 130,000 cases (or more) to identify large
numbers of commonly occurring variants. 15 While biobanks and elec-
tronic health records provide opportunities for increasing sample sizes
for AUD, the ability to adequately assess illicit drug use disorder from
biobanks remains questionable. That said, steady progress is being
made for illicit substances. For example, a recently published GWAS
for opioid use disorder in the Million Veterans Program and two addi-
tional samples, obtained genome-wide significance for rs1799971 in
the gene encoding the mu-opioid receptor, OPRM1, with 8529 cases
and 71,200 opioid-exposed controls22 though additional work is
needed to validate these findings.
It is also important to note that identifying genetically-mediated
mechanisms of disease is also partially contingent on how well a phe-
notype is defined so that it reflects relevant biological and environ-
mental variation. In human GWAS, phenotypic heterogeneity, which
is evident in diagnostic classification, as well as the imprecision of
recall and self-report, has been shown to result in low heritability
(in some instances) and specificity for disease prediction.29 Compared
to humans, model organisms have the advantages of narrowly defined
phenotypic assays applied to both experimental and control groups
and objective measurements. However, animal models poorly reflect
the interpersonal and quality of life aspects of human SUD.30 Human
studies using case–control and quantitative phenotypes of the most
predominantly used substances, alcohol and tobacco, with sufficiently
large sample size have recently confirmed suspected genetic media-
tion of pharmacokinetic and pharmacodynamic pathways; studies also
suggest greater relevance of single nucleotide variants expressed in
brain.31-33 Liu et al.18 found that all central-nervous-system-expressed
nicotinic receptor genes (except for CHRNA7) were significantly asso-
ciated with one or more smoking phenotypes that they examined.
This suggests that related phenotypes, such as age of smoking initia-
tion and cigarettes per day, may show overlapping but differential pat-
terns of associations with relevant genetic variation. Therefore, it is
important to examine a variety of different phenotypes, from case–
control phenotypes to endophenotypes. For example, in a GWAS of a
pharmacologically relevant phenotype for smoking, a measure of the
rate of nicotine metabolism (the nicotine metabolite ratio [NMR]),
identified polymorphisms that account for nearly 40% of the pheno-
typic variance in NMR,34 but these same loci do not have a similarly
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large effect on nicotine dependence. Consequently, there is still a gap
in understanding the broad and substance-specific mechanisms and
the functional significance of DNA variants that have been discerned
to date using endo-, clinical-, and coarse-phenotypes and biomarkers.
Some researchers at the meeting commented that mixed-linear-
model-based and traditional GWAS and quantitative trait locus (QTL)
analyses alone cannot solve these phenotype limitations because the
variance structure of agglomerative phenotypes does not match that
of the genome and the associated structures/tissues. Others coun-
tered that well-powered GWAS complemented by new post-hoc com-
putational methods (e.g., genomic structural equation modeling 35 and
multivariate GWAS,36 to name a few) might surmount minimal
phenotyping limitations. For a detailed example of deep phenotyping
issues in a complex psychiatric disorder, we recommend the recent
paper by Cai et al.29
Based on these observations, researchers recognized that other
methods should help complement and extend well-powered GWAS
methods to address current knowledge gaps in the genetic architec-
ture of SUDs. A notable illustration arises from the characterization of
the complement C4 pathway in schizophrenia, which arose from a
GWAS that identified a strong signal in the MHC locus but required
deep, cross-species cellular and molecular experiments to explicate.
Previous studies15,37 have also indicated this will require (1) larger
sample sizes, (2) better phenotyping, (3) more diverse samples,
(4) improved coverage of genetic variation by GWAS arrays or greater
emphasis on sequencing,38-40 and (5) more comprehensive system-
based models and hypotheses that incorporate epistasis (GxG), envi-
ronmental factors, GxE, and many comorbidities. Systems-based and
multi-level studies would ideally model the complex nature of SUDs
using multiple cofactors (and confounders) and take into account the
inevitability that many agglomerative phenotypes will be made up of
multiple mechanistically distinct sub-phenotypes. In addition to the
more nuanced and precisely defined and quantified phenotypes and
cofactors (e.g., BMI for alcohol41) and confounders,42 such studies
would also incorporate other forms of DNA variation and potential
non-linear (i.e., GxG and GxE) effects although recent studies have
suggested that most of the genetic variance for complex traits appears
to be largely due to additive effects, with negligible dominance
effects, and an indeterminate amount of epistatic effects due to
power and study design issues.43 Still, it is worth noting that a negligi-
ble genome-wide contribution of dominance effects does not pre-
clude the existence of individual loci with a dominant mode of
inheritance. While the importance of these different issues and
approaches was discussed, a diversity of opinions was expressed
about GxG effects, and the group did not reach consensus.
At the sequence level, many studies are also still missing signifi-
cant genetic diversity—particularly from non-European populations.44
Even though copy number variant (CNV) studies of psychiatric disor-
ders are becoming more commonplace,45 mobile element polymor-
phisms, inversions and other types of structural variants are still
missed in GWAS—as are subsets of variants not tagged using standard
GWAS arrays or incorrectly aligned to a single canonical reference
genome. In short, recent insights from past studies highlight how gaps
in our understanding could be addressed using large and genetically
diverse samples (is being achieved for nicotine and alcohol, but not
other substances), better phenotyping, new computational methods,
and long-read sequencing technologies to capture and model causal
genome variants, especially those (e.g., CNVs, insertions, deletions,
and inversions) not well captured by GWAS arrays; see Peterson
et al.46 for a detailed discussion on opportunities for diversity in
GWAS. In addition, single-cell technologies, such as single-cell-RNA-
seq, and complementary approaches toward studying regulatory
effects of variants, among others, will help to better uncover cell-type
specific networks involved in SUDs, as has been documented for
schizophrenia.47 Altogether, these types of systems-based approaches
that incorporate multiple layers of genomic and environmental data
will require advanced methods, that may include multilevel machine
learning, deep learning, and explainable-artificial intelligence tech-
niques to name a few; and these model-free approaches will have to
accommodate features specific to the human genome, such as popula-
tion substructure, which can confound association signals.48 Likewise,
it will require a more comprehensive, integrated capture of
population-scale data at multiple omics layers (genome, epigenome,
transcriptome, metabolome, microbiome) in both model organism and
human studies (see Table 1). Costs for generating multi-omic data,
including brain proteomics and metabolomics are falling rapidly and
making such programs possible.
Complementary to human GWAS, research using model organ-
isms is amassing a large body of evidence supporting causal roles for
many genomic loci and gene variants related to SUDs (e.g., Taar1
for methamphetamine'49 APBA2 for addiction,46 XRCC5 for alcohol
dependence,50 and the use of CRISPy Critters for instance in
alcohol research51). Still, these findings probe only a small part of the
complex central nervous system (CNS) molecular and cellular net-
works affected by addictive substances. There is also deep sequence
data on shorter classes of DNA variants and expression data collected
in many contexts across large populations of key model organisms,
including Drosophila (the Drosophila Genetic Reference Panel),52,53
mouse (Collaborative Cross, the Hybrid Mouse Diversity panel, and
the BXD family, collectively n >200 isogenic strains,54,55 and outbred
mouse populations, including several heterogeneous stocks,56-59
advanced intercross lines60), and rat populations (e.g., Hybrid Rat
Diversity Panel and the National Institute of Health [NIH] heteroge-
neous stock,60 and outbred Sprague Dawley61,62). As a field, behavior
geneticists, both human and animal modelers, are beginning to catalog
and even understand the function(s) of subsets of variants that alter
protein-coding sequence, modulate transcript and protein isoforms, or
change expression.63-65 However, although great progress has been
made, we highlight key gaps:
1. the comparative invisibility of mobile element polymorphisms,
some types of structural variants, simple tandem repeats, and rare
variants, including de novo mutations;
2. the problematic nature of aligning a sequence to a linear reference
genome rather than to pangenomes that are savvy with respect to
sequence differences among individuals and ancestries; and
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humans, but is limited
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Naturally occurring lesions can
be studied
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3. the reliance on simple additive models that cannot detect or are
confounded by gene-by-gene epistatic interactions or cleanly dis-
sect and unconfound GxE effects.64,66
Researchers at the meeting discussed gaps in knowledge and pos-
sibilities for the next phase of functional discovery for substance use
and disorders, which will likely require (1) the construction of appropri-
ate resources for systematic evaluation of loci function in humans,
(2) quantitative experimental studies of SUDs in model organisms with
a more realistic level of genetic complexity, (3) concerted multi-
disciplinary efforts to acquire additional samples for discovery/valida-
tion, and (4) a shift towards causal models and quasi-experimental
research designs in order to understand gene-by-environment, gene-
by-development, and epigenetic modifiers across a range of
genetically-admixed and genetically simple cohorts of model organisms.
2 | THEME A: BRIDGING THE GAP
BETWEEN HUMAN AND ANIMAL RESEARCH
2.1 | Prioritizing variants for functional follow-up
In recent years, larger human GWAS have begun to produce a more
robust and reliable set of genomic loci and gene variants. Similarly, model
system studies complement these phenotype–genotype associations via
behavioral neurogenetic methods, but not without limitations (see
Table 1). Indeed, human and model organism studies offer varying
degrees of power and limitations to identify a gene or network for func-
tional follow-up. For example, human GWAS require very large samples
to study phenotypes that may be less proximal to the biological ele-
ments. Model organisms require smaller sample sizes, but their individual
single nucleotide polymorphisms (SNPs) and genes may not entirely map
onto human biology and the substance use phenotypes that operate in a
complex, human environment. Given that the collection of larger, more
diverse GWAS samples for SUD phenotypes will require targeted data
collection, especially in underrepresented populations, some researchers
at the meeting acknowledged that animal QTL, and other methods
(e.g., recombinant inbred strains55), can help make headway in parallel.
One area for further development includes refinement of efficient and
unbiased computational workflows to rank top variants and map their
target genes and gene, molecular, and cellular networks.
Researchers at the meeting discussed strategies to make
advances in using integrative approaches, which could rapidly locate
and translate loci for SUDs. These strategies combine data from
GWAS in humans with well-matched experimental work in model
organisms—both genetically admixed crosses and gene knockout and
knock-in studies. Ideally, these studies would leverage a universal
platform for sharing current datasets from model organisms with
human GWAS findings, a resource currently lacking. At the time of
this publication, data from model organism studies are largely isolated
by species and even by strain and type. As such, they are often far
from FAIR compliant67 and are just as hard to access and integrate as
GWAS data from heterogeneous human populations, which are not all
shared on the NIH's database of Genotypes and Phenotypes (dbGaP)
or other repositories available to the scientific community. These real-
ities further compound the challenge of rigorously combining human
and animal model data sets (see Section 4 Theme C discussion for
details).
2.2 | Why data integration across species and
multiple omics is important for expansion, discovery,
and translation of genetic risk for SUDs
While there are many differences between behaviors, body, and brain
structures of all model organisms and humans, there is still a high level of
genomic and functional commonality that can be leveraged under tightly
controlled environmental and treatment conditions. In essence, a ran-
domized controlled trial across multiple genotypes can usually be
designed and implemented reasonably easily with model organisms.68
Likewise, causal models can be constructed to evaluate potential con-

























both animal and human
research





psychiatric and other risk
factors
Abbreviations: FUMA, functional mapping and annotation of genetic associations; GWAS, genome-wide association studies; H-MAGMA, hi-C-associated multi-
marker analysis of genomic annotation; LOE, lines-of-evidence; PGS, polygenic score; QTL, quantitative trait locus; RWR, random walk with restart; SUD, substance
use disorder.
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constructed genetic backgrounds of varying disease susceptibility (see
Table 1: areas of convergence). Molecular and cellular endophenotypes
of SUDs are readily accessible in many model organisms. Conservation
of functional genes and networks across species can provide genuine
insight of high translational relevance–particularly when the GWAS
searchlight has illuminated a small number of plausible genes and geno-
mic regions. Because of differing evolutionary histories, individual vari-
ants among humans and model organisms are often not conserved69,70;
however, the prospects of comparing genetically engineered lines to
diverse populations of mice holds significant promise for disease map-
ping and detecting epistatic interactions.55 This apparent gap in the liter-
ature highlighted why analyses are best suited to be conducted at the
level of genes, molecular networks, and gene sets. Still, attendees at the
meeting acknowledged that experimental models could complement
these analyses by providing a reproducible resource to identify funda-
mental processes and modifiers that affect aspects of SUD with the goal
to transition as efficiently as possible to well-reasoned interventions that
reduce SUD burden. Gene network perturbations that are evident in cer-
tain model organism experiments and humans may highlight novel entry
points for pharmaceutical intervention and innovation that would be mis-
sed by the study of humans alone (e.g., modulation of an associated pro-
tein if variants are in a regulatory region). Further, identification of
molecular and cellular networks that contribute to SUD risk, progression,
and relapse will benefit from access to longitudinally collected datasets
to strengthen causal inferences, define and test plausible models, and
refine treatment options on the basis of genotypes and diplotypes.
Human tissues, cells, and organoids are highly useful tools for eluci-
dating molecular and cellular networks in human-relevant model sys-
tems but have fundamental limitations, especially with respect to
higher-order behavioral outcome variables that replicate aspects of
human addiction. While formal proof of the roles of DNA variants is
most readily provided using gene-engineered animals or specific phar-
macological treatments, it is vital to note that “necessary and sufficient”
causal criteria depend greatly on the genomic background.71 Moreover,
gene-engineered models will ideally account for genetic diversity in
order to ensure that results are not only replicable but are likely to have
external validity across species. While some researchers predicted that
data generated from these approaches would show greater consilience
with the diversity of human behavioral outcomes, others contended
that additional research is needed to understand which animal para-
digms and tissues best characterize the basic behavioral properties and
neurobiological components of addiction, respectively.
Many researchers have begun to tackle the issue of variant prioritiza-
tion by integrating multiple sources of information.72-74 Indeed, most
GWAS include detailed post-hoc analyses toward the identification of
credible causal variants. Network integration is one method that can per-
mit the full illumination of patterns that are shared across gene sets
derived from single omics data (e.g., genetic variants, RNA-seq in bulk tis-
sue, single-cell RNA-seq, chromatin immunoprecipitation sequencing
[ChIP-seq], ATAC-seq, methylome, etc.). Variant-based networks can be
mapped onto genes, enabling a common basis for network integration: the
gene level. A range of public data (e.g., ChIP-seq from ENCODE, RNA-seq
from the Genotype-Tissue Expression [GTEx] project,75 Hi-C data for
chromatin structure,76 protein–protein interaction data, etc.) can be incor-
porated to add evidence for the networks' biological plausibility; however
several researchers advised caution as data limitations and improper han-
dling could create biased results. Further sophisticated network layers can
be generated with the use of new explainable-AI tools that can find highly
accurate linear and nonlinear multi-way associations within and across
omics layers;77 though, as shown in the case of machine learning using a
candidate SNPs for opioid dependence, extreme care should be taken to
account for social inequities that permeate research practices and could
likely confound biological mechanisms under study.78 After integrating the
networks from the different data inputs based on gene IDs, lines-of-
evidence (LOE) scoring79 methods offer a way to establish links between
the networks, with each link adding to the score for connecting layers.
Explainable-AI approaches, such as iterative random forest-leave one out
prediction (iRF-LOOP) are able to find linear and linear expression relation-
ships in expression datasets derived from population-scale RNA-seq
datasets and are more accurate than traditional co-expression
approaches.77 These explainable-AI derived networks can be built from
publicly available datasets (such as GTEx) to provide tissue-specific regula-
tory patterns. They can similarly be built of single-cell-RNA-seq datasets
to provide cell-type-specific regulatory networks. Of course, they can also
be built from novel experimental data from individuals who were addicted
to opioids. These networks can be combined with networks derived from
other data types to form a multiplex network. For example, an
explainable-AI-derived RNA expression network associated with opioid
addiction in the nucleus accumbens (NAc) may link to a genome-wide
epistasis (GWES)-based network80 and a NAc-specific network assembled
from the GTEx, and may also connect through to a protein–protein inter-
action network and signaling cascade network all through common gene
IDs. Subsequently, random walk with restart (RWR) approaches, which
use an advanced form of network-association that is not limited to explor-
ing shortest paths or nearest neighbors, can jointly examine these multiple
heterogeneous multiplex networks while retaining the critical topological
information present in each network.81 By jointly integrating multiple het-
erogeneous data layers, one can score and rank candidate genes from
GWAS and genome-wide epistasis study (GWES) analyses using RWR-
based LOE algorithms. This can help to prioritize genes from GWAS/
GWES results and to provide mechanistic context for the resulting filtered
genes sets by way of subnetworks that include the links among members
of the filtered gene set and links to genes highly connected to members of
the gene set in the network. This context greatly enhances mechanistic
interpretation and the creation of conceptual models that can be used to
design validation experiments in human tissue or animal models. Because
similar gene-based networks can also be generated from model organisms,
they can also be integrated with human networks via ortholog projection
in order to leverage information from multiple species.
2.3 | Challenges and knowledge gaps in cross-
species research
There is heterogeneity in the behavioral phenotypes and paradigms
across humans and model organisms, respectively, that needs to be
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considered when attempting to identify the biobehavioral processes
underlying substance use and disorders. Clinical diagnoses of SUDs in
humans are based on assessments of drug-seeking, physical depen-
dence, and social disruption but often struggle to quantify each of
these phenotypes (e.g., the problem of going from a polythetic diagno-
sis to understanding severity/impact of combinations of criteria on a
person's life).82 It is often the case that qualitative symptoms are
employed, and several combinations of criterion endorsements (i.e., 2
or more of 11 DSM-5 symptoms) could result in a diagnosis. This diag-
nostic heterogeneity (i.e., different case subjects meeting the criteria
for endorsing varying sets of symptoms) leads to challenges in genetic
mapping83-85 and alignment with unconditioned and conditioned
quantitative traits used in animal models. In contrast, animal studies
place a high emphasis on measuring quantity/frequency and physio-
logical dependence. Studies of alcohol and cannabis use disorders
have shown quantitative and qualitative differences between the
genetics of consumption quantity and frequency and the genetics of
the disorders (e.g., impaired functioning, physical dependence, disrup-
tion of social responsibilities).12,86 Likewise, a geneset derived from
tobacco exposure paradigms in rodents shows modest enrichment for
the SNP-heritability of human tobacco consumption.87 Notably,
inbred strain comparison/selective breeding studies have allowed sci-
entists to examine the effects of genetic background on multiple
related traits.88 Differences in the phenotypes assessed in humans
and rodents may therefore contribute to a partially disconnected
approach to understanding risk rather than a fully integrated
approach, thus requiring detailed studies of consilience across pheno-
types and omic-phenotype associations. For example, even just within
humans, recent studies suggest that the genetics of human alcohol
consumption, particularly frequency of alcohol intake, is only partly
related to the genetics of alcohol problems (e.g., impaired functioning,
physical dependence, disruption of social responsibilities).19 Likewise,
a geneset derived from tobacco exposure paradigms in rodents shows
modest enrichment for the SNP-heritability of human tobacco con-
sumption.87 Therefore, differences in phenotypes and their associated
genetic architecture, whether within or across organisms, should be
taken into consideration, and leveraged when possible. As mentioned
above, there is tremendous potential to build integrated, cross-species
multi-omics networks that can serve to unify and utilize data and
extant knowledge from both humans and model organisms.
There are several knowledge gaps that, if addressed, would help
inform whether genetic results for SUD phenotypes can be translated
across species. These included understanding (1) the degree of con-
cordance among model organism findings, as well as (2) the extent to
which model organism evidence generalizes to humans, (3) the con-
textual implication of tissue, sex, and ancestry on these effects, and
(4) how unifying phenotypic definitions across databases can enhance
sample sizes and data integration. To date, several studies have shown
enrichment of mouse and rat gene sets (i.e., those that are differen-
tially expressed in the presence of cocaine) in the human brain trans-
criptome for cocaine use disorder, 89 as well as human GWAS of
tobacco/nicotine consumption.87 Identifying convergent genetic
mechanisms between humans and model organisms in SUDs is an
exciting challenge but is (relatively) close at hand. Even more daunting
challenges (and rewards) are presented by the ambitious goal of iden-
tifying neural pathways conserved between model organisms and
humans for addiction and its associated constellation of complex
behaviors. Clearly, the molecular and bioinformatics tools that emerge
from tackling the first problem will be a starting point for attacking
the second.
3 | THEME B: CURRENT TOOLS FOR
INTEGRATION OF GENETIC, EPIGENETIC,
AND PHENOTYPIC DATA
Several tools (e.g., methods, software, databases) currently exist and
are under active development to aid scientists in analyzing and inte-
grating multiple types and streams of data from a wide variety of
model organisms and diverse human populations. Here we highlight a
few that facilitate multi-omics and cross-species research. For a more
comprehensive list of tools please see the paper by Reynolds et al.90
Functional mapping and annotation of genetic associations
(FUMA) was developed 91 to annotate, prioritize, visualize, and inter-
pret GWAS results. The application integrates genome-wide summary
statistics with functional information, such as expression-QTL (eQTL)
and chromosomal interaction mapping in a tissue-specific manner to
identify the most likely causal SNPs. FUMA uses 18 biological data
repositories (e.g., GTEx) and tools to functionally annotate GWAS hits.
FUMA employs two gene-mapping strategies. First, it uses multi-
marker analysis of genomic annotation (MAGMA) to aggregate SNP-
level statistics up to the gene level, which enables more facile follow-
up network analyses. However, MAGMA does not take gene regula-
tory information into account when mapping SNPs to genes. Alterna-
tively, FUMA allows GWAS annotation by leveraging Hi-C and eQTL
data, leveraging available data resources including GTEx, Brain eQTL
Almanac (BRAINEAC),92 CommonMind,93 and PsychENCODE.94
Hi-C-associated multi-marker analysis of genomic annotation (H-
MAGMA) was developed to overcome limitations in MAGMA.95 H-
MAGMA advances MAGMA by incorporating long-range (gene regu-
latory) interactions defined by Hi-C in mapping SNPs to genes. Fur-
ther, it adopts the genome-wide mapping capability of MAGMA and
expands the gene set to follow-up for molecular and biological path-
way analysis. H-MAGMA has been developed on multiple Hi-C
datasets95,96—those obtained from human fetal brains, adult brains,
neurons, and glia sorted from the adult dorsolateral prefrontal cortex
(DLPFC), iPSC-derived neurons, and iPSC-derived astrocytes. This
enables developmental stage and cell type-specific gene mapping.
GeneWeaver is a suite of database and analysis tools that inte-
grate data from expression microarray, RNA-seq, QTL mapping,
GWAS, and mutation and perturbation screening experiments across
species (yeast, worm, fly, zebrafish, mouse, rat, dog, human, and other
species).97-99 It also integrates protein–protein, molecular networks,
and regulatory relationships to impute biological functions of variants
and genes to phenotypes. In addition, GeneWeaver can assess molec-
ular and trait relations through graphical network algorithms that
PALMER ET AL. 9 of 15
leverage gene–gene and variant-variant comparison using complex,
heterogeneous networks and random walk or network flow-based
approaches. Until recently, GeneWeaver has used a gene-based strat-
egy to integrate data because convergence or conservation of mecha-
nism across species has typically relied on gene orthology.
Authoritative data resources, including model organism databases and
the Alliance of Genome Resources, have cataloged orthologous genes
across species based on sequence alignments. Functional genomics
analysis systems, including GeneWeaver, have made use of these
reported orthologues to compare the results of genomic experiments
across species at the gene level. Transitive associations are made to
infer cross-species orthology where sequence alignment has not
inferred a relationship (e.g., a Drosophila: zebrafish orthologue and
zebrafish: mouse orthologue can be used to infer Drosophila: mouse
orthology). Although functional coding variants, such as missense vari-
ants, are enriched among GWAS findings, most genome-wide signifi-
cant variants implicate noncoding regions.33 These noncoding variants
are poorly conserved at the sequence level, and their functional inter-
pretation presents a major challenge for the field. New approaches
are being developed by the GeneWeaver project for mapping noncod-
ing variants across species based on functional similarity and target
orthology using combined genomic data sources. These methods are
being applied to prioritize GWAS-identified variants based on evi-
dence obtained in model organisms.
3.1 | GeneNetwork
GeneNetwork is an interactive system for genome-to-phenome analy-
sis, QTL mapping, and network integration. This resource incorporates
large genetic, multi-omic, and phenotype data sets for highly diverse
animal model populations such as the BXD and CC lines of mice, the
HXB and HS rats, and several large number transcriptome data sets,
including GTEx. GeneNetwork integrates 40 years of animal model
data relevant to NIDA, NIAAA, NINDS, and NIMH missions, starting
with catalytic studies by Crabbe, McClearn, Hitzemann and Flint—
especially data on behavioral variation and its linkage to gene and pro-
tein expression in the central nervous system.55,68,100 The great
majority of data in GeneNetwork is both open and FAIR-compliant
and can be downloaded or used on-site in combination with powerful
mapping modules that include R/qtl,101,102 and the Bayesian network
webserver.103
3.2 | PrediXcan/MetaXcan
PrediXcan was developed as a gene-based association test that priori-
tizes genes likely to be causal for the phenotype, using predicted gene
expression levels, most often with GTEx as the reference.104 S-
PrediXcan is a variation of this test that uses summary statistics
instead of individual-level data. MultiXcan and S-MultiXcan are multi-
variate approaches (in contrast to the single-tissue approaches of Pre-
diXcan/S-PrediXcan) that integrate measurements across tissues
while accounting for correlations. Extensions of this approach are
now being used to transfer polygenic findings from GWAS between
human populations, and the authors suggest that these techniques
might allow translation between species in the future.105 These
methods fall under the family of transcriptome-wide association study
(TWAS)106 approaches more broadly (e.g., Fusion is a similar approach
that can be performed on GWAS summary statistics).106
4 | THEME C: ENSURING THAT DATA ARE
READY FOR INTEGRATION
The long-term data curation and implementation of FAIR data princi-
ples (https://www.go-fair.org/fair-principles/) is integral to the suc-
cess of integrating human and model organism research and multi-
omic data. FAIR standards are particularly important. Without atten-
tion to data accessibility, many large and small SUD-related data sets
risk evaporating over a relatively short period of time—often only 5–
10 years. This is particularly true of animal model data that tends to
be highly granular and often siloed. Data sharing issues aside, there is
a need for (inter)national storage and curation efforts because those
aspects are typically beyond the scope of most research projects.
Continued access to data, regardless of its presumed value, is key to
leveraging future technological advances. There are, however, notable
cases where advances in computing capacity and statistical methods
greatly improve the value of older data. For example, phenotype data
on drugs of abuse acquired over three decades ago can now be rea-
nalyzed using new mapping algorithms (e.g., linear mixed models) and
full genome sequence data. For example, data generated by a team at
ORNL a decade ago68 can be remapped today to generate signifi-
cantly stronger and even novel results than they did initially.
Participants discussed current knowledge gaps related to the
development of metadata standards and data ontologies in order to
move research forward. For instance, the lack of standards for
describing disease phenotypes, such as those developed by the MON-
ARCH initiative (Mondo disease ontology and Human Phenotype
Ontology [HPO];107,108) and the limited amount and quality of derived
phenotypes from electronic health records. Metadata helps with
findability, interoperability, and usability. Because of this, participants
emphasized that distribution platforms and curation tools that make
metadata searchable urgently need further development. Overcoming
these limitations would involve the identification of missing summary
metadata fields for human data in dbGaP, as well as making prior
results and data accessible both in name and in practice. Still, there is
not a standard process for making data more findable and readable.
Participants discussed several possible approaches for making data
more searchable, such as using a Digital Object Identifier (DOI),
machine-readable identification number, and Research Resource Iden-
tifiers (RRIDs)109 as possible strategies to achieving data integration.
As with all large-scale data endeavors, the researchers recognized a
limitation around encryption software that would enable accessibility
of primary raw data and allow searches across databases without the
loss of de-identification. A major benefit of overcoming this limitation
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would be the ability to work with raw data using alternative methods
that meta-analysis does not permit. Similarly, researchers acknowl-
edge the limited number of application programming interfaces (APIs)
to enable interactions between data, applications, and devices. APIs
deliver data and facilitate connectivity between devices and programs.
Compelling prototype solutions are described above, but issues
remain in the widespread integration and adoption of these systems.
The biggest challenges are dynamic updating and organization of data
for sharing and discovery as well as connecting across organisms and
data types (e.g., sequence, epigenomic, etc.). Integration between
graphical and relational databases remains a problem to be solved. To
address these major challenges, participants discussed areas for
improvement, including a lack of understanding of the following:
1. The degree of modularity and interoperability of existing data anal-
ysis software that can be used to facilitate the integration of ChIP-
seq, DNA methylation, Hi-C, RNA-seq, splice variants, and struc-
tural variants information.
2. How gene network, epistasis, and genetic modifiers affect sub-
stance use outcomes.
3. How chromatin organization varies across human brain regions
and in different cell types.
4. Ancestry differences in gene regulation.
5. How chromatin (Hi-C) and methylation (H3K27ac) data can be
combined to predict gene expression with higher accuracy.
6. How models using protein–protein interaction (or similarly relevant
omic data) data can help to improve the performance of existing
genetic prediction tools.
7. How to access raw primary data while maintaining de-identification.
5 | CONCLUSIONS AND FUTURE
DIRECTIONS
Genetics in human and animal models is now providing significant
insights into molecular causes of addiction and SUDs. However, these
leads still require extensive evaluation before being employed as pre-
vention (e.g., to understand the utility of a polygenic score [PGS]
beyond indicators of family history) and intervention tools (e.g., to
reset CNS metabolic and cellular states back to health and well
adapted behavior).110 Major gaps in the field's mechanistic under-
standing of the perturbations underlying SUDs remain. Addressing
these gaps and advancing the field will require attention to the follow-
ing areas: (1) well-powered GWAS of SUDs and relevant human traits
in diverse samples, (2) computational workflows that jointly leverage
model organisms and large human cohorts, (3) generation and integra-
tion of multi-omic data across developmental stages, brain regions,
molecularly defined cell types, and disease conditions, (4) data harmo-
nization across human and model organisms at the level of the pheno-
type, as well as different omic, cellular, and systems levels, and
(5) data curation and sharing.
Meeting participants also discussed key areas for future data inte-
gration, beginning with cross-species research and data integration
tools. Continued research in integrative platforms will allow the exam-
ination of various use cases that will help develop an understanding of
the difficulties and opportunities in data integration. As the goal is to
develop a plausible set of gene networks/sets from robust GWAS and
fine mapping studies in mice and humans, it will be important to con-
sider the nuances of mapping top results based solely on positional
data. For example, previous SUD GWASs limited annotations to genes
nearest to the lead SNP, and only more recently have studies begun
to include tissue-specific annotation methods such as H-MAGMA and
PrediXscan, to name a few. Many researchers are working on system-
atic multi-omic integration approaches to fine map complex genetic
loci and nominate target genes. Reports on the progress of these
efforts began at the Genetics and Epigenetics of Addiction (January
13–14, 2020) and are available at https://www.drugabuse.gov/
research/research-data-measures-resources/genetics-epigenetics-
ccrt/nida-genetics-consortium-ngc/nida-genetic-consortium-
meetings-abstracts. Second, we need an increased understanding of
the neurotoxic and behavioral effects of drugs. This continuously
evolving body of literature will facilitate computational experiments
to identify gene variants in underpowered GWAS. Integrative analyses
in humans that include model organism data could also be applied to
GWAS data as have been realized to date using Bayesian approaches
to optimize gene identification using functional categories in genet-
ics111 and cis- and trans-eQTL information in transcriptomics.112
This Data Jamboree meeting represents a pivotal point in an
ongoing process of information sharing that reflects the interdisciplin-
ary nature of addiction genetics research. Notably, it builds on the
previous report by Cates et al.,113 that emphasized the importance of
harmonizing phenotypes and methods of analysis among studies.
Even though geneticists at this meeting did not always agree on
the ideal course of action for the next phase of discovery, the debate
and dialog, spurred by a shared commitment towards identifying tan-
gible genetic targets, resulted in several new directions for human and
model organism research.
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